Search research articles
Contact Us
Filters
Showing results (201-210 of 290) with videos related to
Page
of 29
Sort By:
The Oncologist
|
July 27, 2019
Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations
William Boisseau, Philipp Euskirchen, Karima Mokhtari, et al.
Clinical Neurology and Neurosurgery
|
June 20, 2020
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma
Antoine Seyve, Fernando Lozano-Sanchez, Alice Thomas, et al.
Neurology
|
August 19, 2018
Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma
Mehdi Touat, Julie Gratieux, Stephanie Condette Auliac, et al.
Cancer Discovery
|
November 29, 2022
LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
Aram Ko, Mohammad Hasanain, Young Taek Oh, et al.
Neuro-Oncology
|
December 17, 2013
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas
Agustí Alentorn, Hinke F van Thuijl, Yannick Marie, et al.
Neuropathology and Applied Neurobiology
|
July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant
Suzanne Tran, Alice Thomas, Ilyes Aliouat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
Murielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.
Neuro-Oncology
|
October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1
Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.
Neuro-Oncology Advances
|
June 10, 2024
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network
Ines Esparragosa Vazquez, Marc Sanson, Olivier L Chinot, et al.
Cancer Biomarkers : Section a of Disease Markers
|
August 12, 2017
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients
Véronique Quillien, Audrey Lavenu, François Ducray, et al.
Page
of 29
Search research articles
Search
Showing results (201-210 of 290) with videos related to
Sort By:
Page
of 29
The Oncologist
|
July 27, 2019
Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations
William Boisseau, Philipp Euskirchen, Karima Mokhtari, et al.
Clinical Neurology and Neurosurgery
|
June 20, 2020
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma
Antoine Seyve, Fernando Lozano-Sanchez, Alice Thomas, et al.
Neurology
|
August 19, 2018
Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma
Mehdi Touat, Julie Gratieux, Stephanie Condette Auliac, et al.
Cancer Discovery
|
November 29, 2022
LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
Aram Ko, Mohammad Hasanain, Young Taek Oh, et al.
Neuro-Oncology
|
December 17, 2013
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas
Agustí Alentorn, Hinke F van Thuijl, Yannick Marie, et al.
Neuropathology and Applied Neurobiology
|
July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant
Suzanne Tran, Alice Thomas, Ilyes Aliouat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
Murielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.
Neuro-Oncology
|
October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1
Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.
Neuro-Oncology Advances
|
June 10, 2024
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network
Ines Esparragosa Vazquez, Marc Sanson, Olivier L Chinot, et al.
Cancer Biomarkers : Section a of Disease Markers
|
August 12, 2017
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients
Véronique Quillien, Audrey Lavenu, François Ducray, et al.
Page
of 29